In RAW 264.7 cell lines, COR inhibits inflammation in vitro via the activation of the LKB1 pathway (LKB1/AMPK/NF-κB and ROS) during the treatment of Kawasaki disease [39] and represses lipopolysaccharide (LPS)-induced inflammation by inhibiting TNF-α and PGE2 [65]. This evidence concerns the gene STK11 and Kawasaki disease.